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Acute kidney injury (AKI) is a renal disease that is associated with high mortality. Current treatments mostly rely on
supportive therapies and do not directly target the disease. Regenerative medicine, however, offers potentially
direct AKI therapy through two strategies: cell transplantation and kidney reconstruction. Regarding cell transplantation,
several cell types are potential sources, including hematopoietic stem cells, mesenchymal stem cells, and renal
stem/progenitor cells within the adult kidney tissue or derived from human-induced pluripotent stem cells
(iPSCs). On the other hand, kidney reconstruction could provide a curative treatment for severe AKI and
consequent chronic kidney disease (CKD). Many methods have been proposed for the kidney reconstruction,
including self-organization, blastocyst complementation, decellularization, and bioartificial kidneys. However,
there are still a number of obstacles to overcome before reconstructed kidneys reach clinical use. In this review, we
summarize the recent progresses in cell transplantation and kidney reconstruction as strategies to treating AKI.Background
Acute kidney injury (AKI) is a frequent renal disease in
hospitalized patients, especially those in intensive care
unit, and is associated with high mortality [1, 2]. Al-
though mild AKI normally recovers, in many cases, se-
vere ischemia leads to chronic inflammation and fibrosis
[3]. Indeed, AKI is a cause of chronic kidney disease
(CKD) and also a risk factor for cardiovascular diseases
[4]. Although effective treatments for AKI are needed,
only supportive therapies are available [5].
Recently, Yamanaka et al. and Thomson et al. simul-
taneously reported the generation of human induced
pluripotent stem cells (iPSCs) [6, 7]. These cells can self-
renew and have the potential to differentiate into any
cell type of the adult body, including renal cells. iPSCs
also eliminate the concern of immune rejection when
transplanted into a patient. These reasons have made
them the basis for cell therapies against various diseases
[8]. Although regenerative medicine for kidney diseases
still remains unavailable because of the complexity of
the organ structure and the incomprehensibility of the
pathophysiology, iPSC technology has allowed for sub-
stantial progress in this field.* Correspondence: osafu@cira.kyoto-u.ac.jp
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(http://creativecommons.org/publicdomain/zeSeveral types of stem and progenitor cells have been
examined as cell sources for regenerative medicine against
kidney diseases. In general, progenitor cells differentiate
from stem cells. These progenitor cells are still immature
and can differentiate into multiple cell lineages but differ
from stem cells in that they lack pluripotency. It is some-
times difficult to distinguish progenitor cells from stem
cells, and thus, the two cell types are often equated. In this
review, therefore, we describe the cells that can specifically
differentiate into kidney lineage cells as “renal stem/pro-
genitor cells” or “renal progenitors.”
When we consider the clinical application of regenera-
tive medicine for AKI, we can classify the strategies mainly
into two groups: (1) cell transplantation and (2) kidney re-
construction. Regarding cell transplantation, transplanted
renal stem/progenitor cells contribute to the host kidney
tissues or secrete paracrine factors that help recovery from
the kidney injury. Several cell types have been reported as
the source for cell therapy, including hematopoietic stem
cells (HSCs), mesenchymal stem cells (MSCs), and renal
stem/progenitor cells within the adult kidney tissue or
those derived from iPSCs. On the other hand, kidney re-
construction might be a curative treatment for severe AKI
and consequent CKD by compensating for the function of
the diseased kidney. Although there are a number of
obstacles to overcome before functional reconstructed
kidney tissues are established, innovative strategies forle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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complementation, decellularized kidney, and bioartificial
kidney, are being developed. In this review, we summarize
the recent progress in these regenerative medicines for
treatment against AKI.
Cell transplantation
Acute tubular necrosis (ATN) is mainly observed in AKI
as a consequence of acute injury induced by multiple
causes, such as ischemia or nephrotoxic agents. After
ATN, renal tubule cells show a tendency to spontan-
eously regenerate, but complete repair is not achieved in
severe cases. Further, if ATN is observed in a large area
of the kidney, interstitial renal fibrosis occurs [9]. It re-
mains controversial whether stem cell populations exist
within the adult kidney and whether they contribute to
the regeneration of renal tubule cells after ATN. Recent
reports have described dedifferentiated cells from renal
tubule epithelia as mainly responsible for the repair of
the renal tubule in AKI [9, 10].
Cell transplantation could help during the repair phase
after ATN. For example, transplanted stem/progenitor
cells could provide additional cell materials for the kidney
regeneration and/or secrete paracrine factors that help the
renal tubule regenerate. A paracrine effect is more likely if
the epithelial dedifferentiation of renal tubule cells is the
main mechanism for recovery from AKI. However, the re-
placement of injured renal tubule cells is also a likely and
intriguing mechanism. Several types of stem/progenitor
cells have been reported as candidate cell sources (Table 1).
Below, we outline how each can be used for treatment
against AKI.
HSCs
HSCs are somatic stem cells in the bone marrow that can
self-renew and differentiate specifically into blood cells,
such as erythrocytes, thrombocytes, and leukocytes. Several
cell surface markers have been identified to isolate HSCs in
mouse and human [11, 12]. HSCs have been reported to
have a therapeutic potential against AKI. For example,Table 1 Characteristics of candidate renal stem/progenitor cells for
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effectsmouse Lin−Sca-1+ HSCs are able to differentiate into renal
epithelial tubule cells [13, 14], and human CD34+ HSCs
were shown to promote the proliferation of both endothe-
lial and epithelial cells after ischemia/reperfusion (I/R) in-
jury [15]. However, there remains dispute about whether
HSCs truly contribute to recovery from ATN in adult ani-
mals, as cell fusion obscures whether HSCs can become
renal stem/progenitor cells [16]. There is also evidence in-
dicating HSCs can exasperate AKI, as it was reported that
an increase in the number of circulating HSCs induced by
pharmacological mobilization from the bone marrow was
associated with increased severity and mortality [17]. Fur-
thermore, the mechanisms by which HSCs protect renal tu-
bules against AKI remain to be clarified. It might be that
HSCs repair the kidney injury by producing protective and
regenerative factors rather than by producing renal stem/
progenitor cells.
MSCs
MSCs are a heterogeneous stem cell population derived
from the bone marrow, adipose tissue, and other organs
but are the easiest to acquire from adipose tissue [18].
MSCs show a fibroblast-like cell shape and can differen-
tiate into cells constituting mesenchymal tissues, which
include cartilage, bone, muscle and fat. MSCs were also
thought to have differentiation potential into kidney
lineage cells and thus could replace destroyed renal cells
[19, 20]. At the same time, it has been reported that
MSCs only remain temporarily in injured kidneys and
show renoprotective function by secreting paracrine factors
that act as anti-apoptotic, mitogenic, anti-inflammatory,
and immune-modulating molecules [21, 22]. MSCs secrete
multiple renotrophic factors, including hepatocyte growth
factor (HGF), insulin-like growth factor-1 (IGF-1), vascular
endothelial growth factor (VEGF), and angiopoietin 1
(ANG-1) [22]. In addition, extracellular vesicles/micro-
vesicles, which contribute to cell-to-cell interactions,
are also candidate therapeutic factors secreted by MSCs
[23]. MSCs have shown therapeutic effects in various
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lar injection of glycerol and by I/R injury [24–27]. Recently,
adipose tissue-derived MSCs were shown to have thera-
peutic benefits against AKI [28–31], which could secure
supply of MSCs and promote the clinical applications. Sev-
eral studies have shown the multiple therapeutic effects of
MSCs in vivo, and phase 1 and phase 2 clinical trials using
MSCs have been done for AKI following cardiac surgery
(#NCT00733876 and #NCT01602328) [32]. However, fur-
ther optimization of the therapeutic protocols, such as the
route of delivery, the volume of the MSC infusion, and the
timing of the administration, is needed [33]. In addition,
despite its promise, it has not yet been reported that MSCs
have protective effects against AKI or other kidney diseases
in human. Additionally, MSCs derived from different adult
and neonatal tissues exhibit heterogeneity and variation in
their surface marker expression and function [18, 34], mak-
ing it difficult to establish clonal MSC populations that have
stable therapeutic effects against AKI.
Adult renal stem/progenitor cells
While recent reports have demonstrated that renal stem/
progenitor populations derived from dedifferentiated renal
tubule cells in the adult kidney are mainly responsible for
the regeneration of renal tubules [9], other stem/progeni-
tor cell types have been isolated from various locations in
the adult kidney [35–39]. Stem cell populations proliferate
very slowly and show specific markers. Taking advantage
of these features, scientists have isolated renal stem/pro-
genitor cells using several methods, such as label-retaining
assays [35, 36], clonogenic cell assays [37], side population
(SP) assays [39], and flow cytometry [38].
Label-retaining cells (LRCs) are identified by the injection
of the thymidine analog 5-bromo-2-deoxyuridine (BrdU)
into mice. BrdU is retained in slow cycling tissue-specific
stem cells. Maeshima et al. used this strategy to find LRCs
in renal epithelial tubular cells, which contribute to tubular
regeneration after I/R injury, in the rat kidney [36].
Kitamura et al. used clonogenic cell assays to establish
clonal cells derived from the S3 segment of rat proximal
renal tubules. These cells showed potent proliferative
capacity and expressed Sca-1, c-kit, and Pax2, markers
of stem cells, and embryonic renal progenitors [37].
Transplantation of the clonal cells significantly improved
the renal function in both cisplatin-induced and I/R AKI
models [40]. Although these cells could differentiate into
tubular epithelial cells, it was suggested that their thera-
peutic effects mainly come from paracrine factors they
produced.
SP assays have been used to purify cells that can efflux
the DNA-binding dye Hoechst 33342 and exhibit stem
cell-like characteristics. These cells are accordingly re-
ferred to as SP cells. Hishikawa et al. clarified the gene
expression profile of kidney SP cells in both renal failuremodels and healthy controls and showed that these cells
express musculin/MyoR [39]. Musculin/MyoR might play
crucial roles in the regenerative processes of the adult kid-
ney. The injection of kidney SP cells improved renal func-
tion in drug-induced nephropathy models, even though
the SP cells located in the interstitial spaces of the kidney
and seemed to exert their therapeutic effects by producing
paracrine growth factors [39].
Regarding stem cells isolated by cell surface markers,
CD133(+)CD24(+) cells have been reported as renal
stem/progenitor cells that localize at the urinary pole of
the Bowman’s capsule in adult human, mouse, and rat
kidneys. When the cells were intravenously injected into
severe combined immunodeficiency (SCID) mice with
AKI induced by rhabdomyolysis, they integrated into the
host renal tissues, differentiated into glomerular podocytes
and renal tubular epithelium, and replaced the injured
renal cells [38].
Among the renal stem/progenitor populations described
above, only LRCs and CD133(+)CD24(+) cells produce
their therapeutic benefits against AKI by integrating into
the adult renal tubules as the main mechanism. The other
stem/progenitor cell populations can improve AKI but
do so mainly by secreting paracrine factors. LRCs and
CD133(+)CD24(+) cells too likely secrete paracrine fac-
tors. In general, however, the considered stem/progenitor
cells have not been fully characterized in terms of their or-
igins or the molecular nature of their paracrine factors.
Further, it is difficult to obtain a sufficient number of these
cells from adult kidneys for treatment. In addition, there is
a risk of immunorejection. Further studies are needed be-
fore these cells have clinical use.
Renal stem/progenitor cells differentiated from
pluripotent stem cells
Recently, two reports including one from our group have
shown the therapeutic effects of renal progenitor cells
differentiated from human iPSCs against AKI [41, 42].
Because of the potential to infinitely proliferate and bypass
immunorejection issues, iPSCs are considered a more
stable and suitable cell source for renal stem/progenitor
cells. We thus aimed to establish a method by which
iPSCs can be differentiated into embryonic renal progeni-
tor cells that have the capacity to further differentiate into
nephron-forming glomerular and renal tubular cells.
In the developmental process, renal progenitors exist
in metanephric mesenchyme (MM), which is derived
from intermediate mesoderm (IM) [43]. Lineage-tracing
analyses showed that Odd-skipped related 1 (Osr1) is
one of the earliest markers of IM [44]. We generated
OSR1-GFP knockin human iPSC lines and established
efficient methods to induce OSR1+ IM cells using a
combination treatment with growth factors and small
molecules [45, 46]. Osr1 is expressed in renal progenitors
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plate mesoderm of early-stage mouse, chick, and fish em-
bryos [44, 47, 48]. On the other hand, renal progenitors in
MM express the homeodomain transcriptional regulator
Six2 in addition to Osr1, although Six2 is also expressed in
other fetal organs, such as the skeletal muscle, limbs,
heart, eyes, and middle ears [49, 50]. Additionally, Osr1
and Six2 interact synergistically to maintain nephron pro-
genitor cells in MM [51]. We thus defined OSR1+SIX2+
cells as renal progenitors.
In order to establish a multistep differentiation protocol
from human iPSCs into OSR1+SIX2+ renal progenitors,
we derived OSR1-GFP/SIX2-tdTomato double knockin
human iPSC lines [41]. We differentiated the human iPSC
line into OSR1+ IM cells using our robust differentiation
protocol and then screened for growth factors and com-
pounds that can further differentiate OSR1+ IM cells into
OSR1+SIX2+ renal progenitors. As a result, we found that
the combination of transforming growth factor (TGF)β1
isoforms and bone morphogenetic protein (BMP) signal
inhibitors, such as DMH1, induced OSR1+SIX2+ renal
progenitors (Fig. 1). We confirmed that the induced OSR1
+SIX2+ cells expressed other renal progenitor markers and
that these cells reconstituted three-dimensional (3D) renal
structures in vitro and in vivo, although they could mainly
differentiate into renal tubule cells.
Assuming that OSR1+SIX2+ renal progenitors could
replace and regenerate renal tubule cells in AKI, we
injected them into the kidney parenchyma of mouse
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Fig. 1 Differentiation protocol for inducing human iPSCs into OSR1+SIX2
OSR1+SIX2+ renal progenitors with embryoid body (EB)-based 3D culture
TTNPB an analog of retinoic acid, DMH1 a selective BMP antagonist, FBS f
replacement, 2ME 2-mercaptoethanol, NEAA non-essential amino acid, BM
Adapted from Toyohara et al. [41]small number of OSR1+SIX2+ renal progenitors were in-
tegrated into the host renal tubules, and no therapeutic
benefit was observed. Then, we transplanted OSR1+SIX2+
renal progenitors into the renal subcapsular space,
expecting that paracrine factors secreted from the renal
progenitors might exert therapeutic effects. Indeed,
AKI in mice induced by I/R injury was ameliorated, as
indicated by the significant suppression of elevated blood
urea nitrogen (BUN) and serum creatinine (Cre) levels
(Fig. 2a) and attenuation of histopathological damages,
such as urinary cast formation and tubular necrosis.
Notably, the treatment improved interstitial fibrosis at
day 12 after I/R, which suggests the possibility of prevent-
ing the progression to chronic disease (Fig. 2b). We then
examined the molecular identity of the paracrine factors
secreted from the OSR1+SIX2+ renal progenitors by micro-
array and multiplex protein detection analyses, identifying
them, such as ANG-1, VEGF, and HGF. Our results dem-
onstrate that the transplantation of renal progenitors de-
rived from human iPSCs has therapeutic benefits against
AKI, mainly by producing trophic effects [41].
Imberti et al. have also reported that the transplantation
of renal progenitors differentiated from human iPSCs im-
proves AKI [42]. The group differentiated renal progenitors
using numerous growth factors and compounds, including
activin A, fibroblast growth factor (FGF)2, BMP7, glial
cell line-derived neurotrophic factor (GDNF), retinoic
acid, phosphoinositide 3-kinase (PI3K) inhibitor, and ras
homologue gene family member A (RhoA) inhibitor.
Cisplatin-induced kidney injury was used as an AKI mouse4egatS3
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+ renal progenitors. The differentiation method used to generate
s. CHIR99021 an inhibitor of glycogen synthase kinase 3 (GSK3),
etal bovine serum, P/SM penicillin streptomycin, KSR knockout serum
P bone morphogenetic protein, TGF transforming growth factor.
ADays after I/R and transplantation Days after I/R and transplantation
B
Saline iPSC-RPs
Fig. 2 Cell therapy using human iPSC-derived renal progenitors ameliorates acute kidney injury in mice. a Time course of blood urea nitrogen
(BUN) and plasma creatinine (Cre) levels in acute kidney injury (AKI) mouse models induced by ischemia/reperfusion (I/R) injury that received the
renal subcapsular transplantation of human iPSC-derived renal progenitors (iPSC-RPs, triangle), undifferentiated iPSCs (iPSCs, square), or saline
(circle). Statistically significant: ***p < 0.001 versus saline, ††p < 0.01 versus iPSCs, †††p < 0.001 versus iPSCs. b Section images of representative
kidney tissue samples from host mice that received an injection of saline (left panel) or the transplantation of iPSC-RPs (right panel). Masson’s
trichrome staining images on day 12 after I/R injury and transplantation. Scale bars, 20 μm. Adapted from Toyohara et al. [41]
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AKI mouse model were different from our report, the
transplantation of renal progenitors in their study also im-
proved AKI. Other large differences between the two stud-
ies include the transplantation method and the integration
of the renal progenitors into the host mouse kidney. The
group injected the renal progenitors through the mouse tail
vein and confirmed that most cells remained in the host
kidney and integrated into the host renal tubules. Although
there is still the possibility that paracrine factors secreted
from the progenitors may be mainly responsible for the ob-
served therapeutic effects, it was suggested that the ameli-
oration of AKI was the result of the integration of the renal
progenitors into host renal tubules.
These two studies show the potential of regenerative
therapy for kidney diseases using human iPSC-derived
renal progenitors. However, optimization of the directed
differentiation and transplantation of progenitor cells is
needed. Further characterization of human iPSC-derived
renal progenitors is also required.
Kidney reconstruction
Although the reconstruction of the whole kidney might
solve the problem of donor organ shortage in kidneytransplantation and become a radical treatment for kidney
disease, there remain a number of technical obstacles to
overcome. Some may be solved using innovative strategies,
such as self-organization, blastocyst complementation,
decellularized kidney, and bioartificial kidney.
Self-organization
Self-organization is the process where stem/progenitor
cells spontaneously reconstitute mini-organs in a 3D
culture. This ability makes self-organization a potentially
powerful tool for generating 3D models of human organ
development. Recently, several groups have differentiated
human iPSCs or human embryonic stem cells (ESCs) into
renal progenitor cells and reconstituted 3D kidney-like
structures using self-organization.
Our group has reported methods for inducing renal
progenitor cells from human iPSCs/ESCs using stepwise
differentiation and chemical biology strategies [41, 45, 46].
By screening growth factors and chemical compounds that
can induce renal progenitor cells from human iPSCs,
we could induce OSR1+ IM cells and OSR1+SIX2+ renal
progenitors. We also reconstituted 3D nephron-like struc-
tures in vitro that mainly contain proximal renal tubules
[41, 45, 46].
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ESCs were differentiated into the progenitors like ur-
eteric bud (UB), an embryonic cell population that gives
rise to the collecting system and the lower urinary tract
from the renal pelvis to a part of the urinary bladder
[52]. Consistently, UB lineage markers, such as HOXB7,
RET, and GFRA1, were upregulated in the induced
cells. These UB-like progenitors could also assemble the
chimeric 3D kidney-like structure with mouse metaneph-
ric cells. Two other studies performed by Lam et al. and
Kang et al. have also developed original differentiation
protocols to generate nephron progenitor cells using 2D
adherent cultures and generated 3D nephron-like struc-
tures containing renal tubules [53, 54]. However, the re-
capitulation of 3D kidney structures containing glomeruli,
renal tubules, and collecting ducts in vitro has remained
challenging.
Significant advances in the generation of 3D kidney-
like structures using renal progenitor cells derived from
human iPSCs/ESCs have also been made [55–58]. These
studies established stepwise protocols that mimic kidney
development. Taguchi et al. demonstrated by the lineage
analysis of mouse embryonic kidney that nephron pro-
genitors in MM are derived from the cell population in
posterior nascent mesoderm at embryonic day (E) 8.5
where Brachyury, a marker of primitive streak, is expressed
while OSR1 is not [55]. They also found that UB is derived
from the cell population in anterior IM, which expresses
OSR1 but not Brachyury at E8.5. Accordingly, they estab-
lished stepwise protocols to differentiate both mouse ESCs
and human iPSCs into nephron progenitors. These progen-
itors could reconstitute 3D nephron-like structures con-
taining glomeruli and renal tubules by coculture with the
mouse embryonic spinal cord [55]. Takasato et al. induced
primitive streak from human ESCs. They then used FGF9
as a factor to induce IM from the primitive streak and gen-
erated a self-organizing structure that included both MM
and UB lineage cells [56]. The same group modified their
differentiation protocol to increase the proportion of MM
and succeeded in generating 3D kidney-like structures from
human iPSCs that contained glomeruli, renal tubules, and
collecting ducts surrounded by renal interstitium and
vascular endothelial cells [57]. Furthermore, endocytosis
of dextran and apoptosis in response to cisplatin were ob-
served in the proximal renal tubules within the kidney-like
structures, indicating that the 3D kidney-like structures
could be used for drug nephrotoxicity tests. This simple
differentiation protocol can generate the most complete
kidney-like structures to date. Morizane et al. induced
SIX2+SALL1+WT1+PAX2+ nephron progenitors from
both human ESCs and iPSCs at 90 % induction efficiency
and used the self-organization of these progenitors to
reconstruct 3D nephron-like structures that expressed
markers for podocytes, proximal renal tubules, loops ofHenle, and distal renal tubules [58]. The kidney-like struc-
tures also showed the upregulated expression of kidney in-
jury molecule (KIM)-1, a marker of AKI, in response to
treatment with gentamicin or cisplatin. Although these 3D
kidney-like structures are still immature and resemble
human fetal kidney [57], they have tremendous potential
for the study and treatment of AKI.
Blastocyst complementation
In blastocyst complementation, ESCs/iPSCs are injected
into the blastocysts, which are embryonic structures formed
after fertilization. Injected ESCs/iPSCs synchronize with the
development of the host embryo to generate a chimeric
animal. When ESCs/iPSCs are injected into the blastocysts
of animals in which the essential gene for the development
of certain organs is knocked out, they can complement the
organ formation. In the first report of blastocyst com-
plementation, Chen et al. injected wild-type mouse ESCs
into the blastocysts of knockout mice for recombination-
activation gene 2 (Rag2), an indispensable enzyme for the
rearrangement of immunoglobulin and T cell receptor
genes [59]. In these chimeric mice, T and B cells were de-
rived from the injected ESCs. Kobayashi et al. reported that
whole pancreas was formed in Pdx1−/− pancreatogenesis-
disabled mice by blastocyst complementation injecting
wild-type mouse ESCs and iPSCs [60]. In the same study,
they also showed that rat iPSCs could generate rat pancreas
in Pdx1−/− mouse by blastocyst complementation. These
results indicate human iPSC-derived pancreas tissues could
be generated in other animals, such as pig, by blastocyst
complementation, although the stromal components, which
include the vessels and nerves in the generated pancreas,
are derived from the host animal. Blastocyst complementa-
tion has also been applied to kidney reconstruction as well
[61]. Renal tissues derived from MM were generated by
blastocyst complementation using knockout mice of the
Sall1 gene, which is essential for the development of MM.
However, renal tissues derived from UB and the vascular
and nervous systems originated from the hosts, not from
the injected mouse iPSCs. Additionally, unlike pancreas, rat
iPSCs failed to form rat kidneys by blastocyst complemen-
tation using mouse blastocysts. Still, although there remain
a number of technical hurdles to overcome, blastocyst com-
plementation is expected as a viable method to reconstruct
whole kidney organs.
Decellularized scaffold
The extracellular matrix (ECM) provides a scaffold spe-
cific for certain cell types within an organ and enables
normal organ function [62]. Several studies have re-
ported that the perfusion of detergents decellularizes the
organs and generates 3D scaffolds. The first report using
this strategy was on the rat heart, which was decellularized
by coronary perfusion and repopulated with neonatal
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muscle cells. After 8 days of the repopulation, contraction
and pump function of the heart were observed [63]. Other
organs, such as the liver and lung, have also been recon-
structed using decellularized scaffolds [64, 65], as too has
kidney. Ross et al. decellularized rat kidneys and reseeded
them with undifferentiated mouse ESCs. The ESCs subse-
quently lost their embryonic appearance and expressed
renal markers, including Pax2 and Ksp-cadherin [66].
Song et al. decellularized rat, porcine, and human kidneys
by detergent perfusion and then reseeded the decellular-
ized rat kidneys with endothelial and epithelial cells. The
construct was perfused with media in a sterilized organ
bioreactor that acted as a closed system. The recon-
structed kidneys expressed markers for podocytes and
renal tubules. Furthermore, urine was generated from the
reconstructed kidney after orthotopic transplantation into
rat [67]. In general, the key to successful decellularized
scaffold methods is identifying which cells should be used
for the reseeding.
Bioartificial kidney
Hemodialysis and hemofiltration therapies have substan-
tially contributed to curing patients who suffer from
AKI or CKD. Although these treatments can excrete
small molecules and substitute for some renal functions,
they cannot completely replace the transport and endo-
crinologic functions of renal tubule cells. Therefore, the
replacement of renal tubular functions has been investi-
gated using bioartificial kidneys. Humes et al. developed
a therapeutic device in which porcine renal tubule cells
were attached inside polysulfone hollow fibers that were
installed in an extracorporeal perfusion circuit [68]. Im-
portantly, clinical trials using this approach reported bet-
ter survival and more rapid recovery from AKI [69, 70].
Saito et al. also reported a bioartificial renal tubule de-
vice that reduces the expression levels of inflammatory
cytokines and increased the life span of AKI goats [71].
These results suggest bioartificial devices may diminish
the morbidity and mortality of AKI patients [72, 73],
but the type(s) of renal tubule cells used needs further
consideration.
Hurdles to overcome
Although regenerative therapy for AKI has been vigor-
ously examined, there remain many hurdles for its clin-
ical application. As for cell transplantation, the route of
cell delivery and the volume of cells to be transplanted
need to be optimized. Currently, deliver methods include
directly injecting cells into the renal parenchyma and
renal subcapsular space and also using transvascular ap-
proaches, but all have flaws. Injection into the renal par-
enchyma allows cells to directly approach the injured
kidney tissues, which might be advantageous for the cellsto integrate into the host kidney tissues. However, this
approach injures the host kidneys themselves, which may
cause severe bleeding and deterioration of renal functions.
Transplantation into the renal subcapsular space, on the
other hand, is relatively safe and suitable for exerting para-
crine effects, but integration of the transplanted cells into
the host kidney tissues might occur at low efficiency. Fi-
nally, although transvascular approaches may be technic-
ally the easiest, the transplanted cells are distributed into
other organs and risk embolization. The integration of
transplanted cells into the host kidney tissues is also diffi-
cult with this approach.
While studies using mice should help optimize cell
therapies, mouse AKI models may have different etiologies
from the human disease. Additionally, species differences,
such as body size and anatomy, make it difficult to ex-
trapolate disease model results to clinical practice. Preclin-
ical studies using animals that are closer to human, like
monkeys and pigs, would be needed before clinical trials.
Kidney reconstruction could be a radical treatment
and applied to almost all kinds of AKI, including those
resulting from pre- and post-renal failure as well as ATN.
However, there are still several obstacles before we could
replace failed kidneys with reconstructed ones. Function
and safety for clinical application of reconstructed kidneys
need to be confirmed. The reconstruction of the urinary
drainage tracts must also be addressed. Recently, Yokote
et al. developed an excellent urine excretion strategy [74].
They transplanted pig and rat MM with the cloaca into
host animals and then allowed the grafts to develop into
functional kidney that filtrated urine from the host blood
stream. They connected the host animal’s ureter to the
bladder developed from the transplanted cloaca. This
strategy avoided hydronephrosis, and the developed
kidney consequently discharged urine via the recipient’s
ureter.
Conclusions
In this review, we summarize the two main regenerative
medicine strategies for the treatment of AKI: cell trans-
plantation and kidney reconstruction. Of the two, cell
transplantation is far more established and can be used
in AKI cases that are not severe. Cell therapy operates
by replacing the injured renal tubule cells with renal
stem/progenitor cells or by exerting paracrine effects
with trophic factors secreted from renal stem/progenitor
cells that help the injured renal tubules regenerate. Can-
didate cells include HSCs, MSCs, or renal progenitors
isolated from adult kidneys or induced from iPSCs. Of
these, iPSCs show the promise, as they are relatively easy
to establish and infinitely proliferate. However, efficient
differentiation protocols for renal progenitors remain to
be established before iPSCs can be used to treat AKI
clinically. In the most severe cases of AKI, a more
Toyohara and Osafune Renal Replacement Therapy  (2016) 2:34 Page 8 of 9ambitious strategy, kidney reconstruction, is being con-
sidered. Here, whole kidneys are being reconstructed in
the lab for replacing the diseased kidney. This strategy
aims to comprehensively recapitulate renal function. In
cell transplantation and kidney reconstruction, consider-
ing recent progress made in these fields, the next decades
will see tremendous advances.
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